First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS G12C -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Pasi A. Jänne, Willemijn S.M.E. Theelen, Marina Chiara Garassino, Alexander I. Spira, Janessa J. Laskin, Filippo de Marinis, Firas Benyamine Badin, Lisenka Boom, Carlos Aguado De La Rosa, Izabela Chmielewska, Enriqueta Felip, Gyula Ostoros, Lauren Jimenez-Kurlander, Cassie M. Lane, Archie Sachdeva, Laura Eccles, Shun Lu
Institutions: Dana-Farber Cancer Institute, The Netherlands Cancer Institute, University of Chicago, Virginia Cancer Specialists, BC Cancer Agency, European Institute of Oncology, Central Baptist Hospital, Ziekenhuis Bethesda, Ziekenhuis Amstelland, Ziekenhuis Bernhoven, St Clara Hospital, Hospital Clínico San Carlos, Medical University of Lublin, Universitat Autònoma de Barcelona, Vall d'Hebron Institute of Oncology, Országos Korányi Tbc és Pulmonológiai Intézet, Bristol-Myers Squibb (United States), Shanghai Jiao Tong University, Shanghai Chest Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410803051